Sensitivity and reproducibility improvements in a human plasma immunoassay with removal of clotting factors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwak, Jiwon | - |
dc.contributor.author | Lee, Soo Suk | - |
dc.date.accessioned | 2021-08-11T09:23:34Z | - |
dc.date.available | 2021-08-11T09:23:34Z | - |
dc.date.issued | 2019-11-15 | - |
dc.identifier.issn | 0003-2697 | - |
dc.identifier.issn | 1096-0309 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4075 | - |
dc.description.abstract | Interferences in human plasma immunoassay are severe challenge that affects the sensitivity and reproducibility of the assay. The clotting factor fibrinogen is a negatively charged protein and is one of the most common sources of interference in immunoassays, and its removal increases the sensitivity and reproducibility. Here, we present a highly sensitive and reproducible method for the detection of prostate specific antigen (PSA) in human plasma immunoassays. Protamine sulfate, a highly positively charged protein, was used to precipitate fibrinogen via ionic interaction to improve the sensitivity and reproducibility of human plasma immunoassay. In a sandwich ELISA for PSA using plasma and prolamine-treated plasma samples, the limit of detection was improved from 413 pg/mL in plasma to 235 pg/mL in prolamine-treated plasma samples, and the coefficient of variation known as a measure of reproducibility was significantly lowered by prolamine treatment. The use of prolamine sulfate in human plasma immunoassays for detection of PSA using quartz crystal microbalance (QCM) biosensors resulted in increased sensitivity and reproducibility by about 2-fold and 3-fold, respectively, relative to when not using prolamine sulfate. Based on these results, prolamine sulfate was the best choice to increase the sensitivity and reproducibility in immunoassays using plasma samples. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Academic Press | - |
dc.title | Sensitivity and reproducibility improvements in a human plasma immunoassay with removal of clotting factors | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.ab.2019.113410 | - |
dc.identifier.scopusid | 2-s2.0-85071435649 | - |
dc.identifier.wosid | 000518175200011 | - |
dc.identifier.bibliographicCitation | Analytical Biochemistry, v.585 | - |
dc.citation.title | Analytical Biochemistry | - |
dc.citation.volume | 585 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
dc.subject.keywordPlus | PROSTATE-SPECIFIC ANTIGEN | - |
dc.subject.keywordPlus | HUMAN-SERUM | - |
dc.subject.keywordPlus | WHOLE-BLOOD | - |
dc.subject.keywordPlus | BIOSENSORS | - |
dc.subject.keywordPlus | FIBRINOGEN | - |
dc.subject.keywordPlus | ASSAY | - |
dc.subject.keywordAuthor | Immunoassay | - |
dc.subject.keywordAuthor | Fibrinogen interference | - |
dc.subject.keywordAuthor | Protamine sulfate | - |
dc.subject.keywordAuthor | Enzyme-linked immunosorbent assay | - |
dc.subject.keywordAuthor | Quartz crystal microbalance sensor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.